Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT400X
- Development stage
- Preclinical
- Lead developer
- Vigeo Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VT400X is a preclinical-stage monoclonal antibody developed by Vigeo Therapeutics for the treatment of various cancers. It specifically targets PRSS2 (Serine protease 2), a protein often overexpressed in the tumor microenvironment that promotes tumor progression, metastasis, and immune evasion. By inhibiting PRSS2, VT400X aims to disrupt these pro-tumorigenic pathways and enhance anti-tumor immune responses. The drug is part of Vigeo's pipeline focusing on novel targets within the tumor microenvironment to overcome resistance to current therapies.
02
Targets
CD36 (CD36 antigen)CD47 (Cluster of Differentiation 47)PRSS2 (Trypsin-2)
Beyond the preview
Go deeper on VT400X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT400X.